Ascendiant Capital Initiates Aldeyra Therapeutics With Buy

Loading...
Loading...
Analysts at Ascendiant Capital initiated coverage on Aldeyra Therapeutics
ALDX
with a Buy rating. The target price for Aldeyra Therapeutics is set to $16. Aldeyra Therapeutics' shares fell 1.09% to close at $7.26 yesterday.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsAscendiant Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...